Bladder cancer: trials for referral
688 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 688 open trials.
Phase 11 site
Not yet recruitingChina
NCT07853053
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pre-treatment window Registry sentence: “Prior systemic anticancer treatment for advanced, recurrent, or metastatic bladder cancer, including chemotherapy, immunotherapy, targeted therapy, antibody-drug conjugates (ADCs), or other investigational anticancer agents.”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 33 sites
Not yet recruitingGermany
2026-527617-29-00
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
Systimmune Inc.
Registry updated 5 Nov 2026
Registry record: EU CTISNo phase1 site
RecruitingUnited States
NCT00026884
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingGermany
NCT03374267
Registry Platform Urologic Cancer
iOMEDICO AG
Pre-treatment window Registry sentence: “Patients with prior systemic therapy for aRCC or aUBC”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 171 sites
RecruitingSpain, France, United Kingdom, Israel, South Korea, United States
NCT07206225
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Pfizer
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT00001823
Evaluation for NCI Surgery Branch Clinical Research Protocols
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 2/3258 sites
RecruitingUnited States
NCT04628767
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 130 sites
RecruitingCanada, China, Spain, United Kingdom, Puerto Rico, United States
NCT07090499
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 183 sites
RecruitingAustralia, Canada, China, Germany, Spain, France
NCT05614739
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 2582 sites
RecruitingPuerto Rico, United States
NCT03866382
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to (Cohort G) : Micropapillary (Tumor should show predominantly \> or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly \> or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed.”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 139 sites
RecruitingAustralia, China, Spain, France, United Kingdom, Japan
NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
Pre-treatment window Registry sentence: “Cohort D: Treatment-naive for locally advanced or metastatic urothelial cancer.”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 2/3505 sites
RecruitingCanada, United States
NCT05987241
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
National Cancer Institute (NCI)
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase751 sites
RecruitingUnited States
NCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 254 sites
RecruitingAustralia, Canada, Switzerland, China, Denmark, Spain
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase30 sites
RecruitingUnited States
NCT07059884
Distance-Based Exercise to Preserve Function and Prevent Disability
Alliance for Clinical Trials in Oncology
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT05672615
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Johns Hopkins University
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase2 sites
RecruitingUnited States
NCT05792722
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
Johns Hopkins University
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase17 sites
RecruitingUnited States
NCT05366881
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela, Inc
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 3163 sites
RecruitingUnited States
NCT06524544
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 242 sites
RecruitingSpain, Georgia, South Korea, United States
NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase45 sites
RecruitingUnited States
NCT06995898
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT07187063
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Lahey Clinic
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 15 sites
RecruitingAustralia, Canada, Japan, United States
NCT07660055
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Novartis Pharmaceuticals
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 3131 sites
RecruitingArgentina, Australia, Belgium, Brazil, Canada, China
NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Merck Sharp & Dohme LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingSpain, Japan, United States
NCT07416123
A Study of GEN1106 in Participants With Solid Tumors
Genmab
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 3121 sites
RecruitingArgentina, Belgium, Brazil, China, Germany, Spain
NCT06919965
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07646145
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Shanxi Province Cancer Hospital
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingHong Kong SAR China
NCT06281080
Performance, Feasibility, and Safety Study for a Novel Endoluminal Robotic System for En-Bloc Resection of Bladder Tumours: First-In-Human Trial
Chinese University of Hong Kong
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 2182 sites
RecruitingUnited States
NCT07061964
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
National Cancer Institute (NCI)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07914101
Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer
Assiut University
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States212 open trials
- China79 open trials
- France56 open trials
- Spain53 open trials
- Italy43 open trials
- Canada33 open trials
- Germany31 open trials
- Australia31 open trials
- United Kingdom28 open trials
- South Korea26 open trials
- Netherlands25 open trials
- Japan22 open trials
- Belgium19 open trials
- Israel18 open trials
- Poland15 open trials
- Denmark12 open trials
- Taiwan11 open trials
- Norway10 open trials
- Brazil10 open trials
- Argentina9 open trials
- Switzerland8 open trials
- Greece8 open trials
- Hong Kong SAR China8 open trials
- Sweden7 open trials
- Czechia6 open trials
- Austria6 open trials
- Chile5 open trials
- Ireland4 open trials
- Bulgaria4 open trials
- Hungary4 open trials
- Romania4 open trials
- Portugal3 open trials
- Puerto Rico2 open trials
- Georgia2 open trials
- New Zealand2 open trials
- Ukraine2 open trials
- Thailand2 open trials
- Latvia2 open trials
- Russia2 open trials
- India2 open trials
- Singapore2 open trials
- Lebanon1 open trials
- Mexico1 open trials
- South Africa1 open trials
- Colombia1 open trials
- Peru1 open trials
- Uganda1 open trials
- Estonia1 open trials
- Greenland1 open trials
- Finland1 open trials
- Vietnam1 open trials
- Iceland1 open trials
- Egypt1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Turin, Italy
0 trials · 13 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 26 publications · ROR
Institut universitaire du cancer de Toulouse Oncopole
Toulouse, France
0 trials · 14 publications · ROR
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Bologna, Italy
0 trials · 13 publications · ROR
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy
2 trials · 18 publications · ROR
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan
13 trials · 22 publications · ROR
Merck & Co., Inc., Rahway, NJ, USA (United States)
Rahway, United States
0 trials · 24 publications · ROR
Rutgers, The State University of New Jersey
New Brunswick, United States
2 trials · 13 publications · ROR
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
0 trials · 16 publications · ROR
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, United States
1 trials · 16 publications · ROR
The University of Texas MD Anderson Cancer Center
Houston, United States
15 trials · 81 publications · ROR
The University of Texas Southwestern Medical Center
Dallas, United States
7 trials · 77 publications · ROR
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, United States
4 trials · 17 publications · ROR
University of California, San Francisco
San Francisco, United States
17 trials · 33 publications · ROR
University of North Carolina at Chapel Hill
Chapel Hill, United States
6 trials · 31 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Closed for recruitment
Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor
NCT07165236 · No phase · Croatia
Source: ClinicalTrials.govOpened for recruitment
NCT07566156 · Phase 3 · Canada, Germany, Spain, France, Italy, South Korea
Source: ClinicalTrials.govOpened for recruitment
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT06668493 · Phase 1/2 · Spain, France, Netherlands, United States
Source: ClinicalTrials.govOpened for recruitment
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govPhase changed: Phase 1 → Early Phase 1
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govClosed for recruitment
NCT06632951 · Phase 2 · Belgium, Canada, Spain, France, Israel, Japan
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
The Impact of PDD During TURB for NMIBC
NCT06548438 · Phase 4 · Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT06483334 · Phase 1/2 · Canada, Denmark, Spain, France, United Kingdom, Israel
Source: ClinicalTrials.govOpened for recruitment
NCT06511648 · Phase 2 · Spain, France, United Kingdom, Italy
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 2
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
NCT06237920 · Phase 2 · Netherlands
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 1/2
NCT06305767 · Phase 1/2 · Australia, Canada, Chile, Colombia, Germany, Spain
Source: ClinicalTrials.govClosed for recruitment
NCT05911295 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05845814 · Phase 1/2 · Australia, Canada, Chile, Spain, France, United Kingdom
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05544552 · Phase 1/2 · Australia, Spain, France, Italy, United States
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
NCT05200988 · Phase 2 · Netherlands
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04660344 · Phase 3 · Argentina, Belgium, Brazil, China, Colombia, Czechia
Source: ClinicalTrials.govPhase changed: Phase 4 → Phase 3
NCT04241185 · Phase 3 · Australia, Chile, Czechia, Denmark, Estonia, Spain
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04044859 · Phase 1 · Canada, Spain, United States
Source: ClinicalTrials.govClosed for recruitment
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
NCT03697850 · Phase 2 · France
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT02138734 · Phase 1/2 · Germany, India, United States, South Africa
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 1/2
NCT02138734 · Phase 1/2 · Germany, India, United States, South Africa
Source: ClinicalTrials.govOpened for recruitment
NCT05911295 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT04678362 · Phase 2 · France
Source: ClinicalTrials.govOpened for recruitment
NCT06632951 · Phase 2 · Belgium, Canada, Spain, France, Israel, Japan
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT06668493 · Phase 1/2 · Spain, France, Netherlands, United States
Source: ClinicalTrials.govClosed for recruitment
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT06637423 · Phase 1/2 · Canada, Spain, France, United Kingdom, Netherlands, United States
Source: ClinicalTrials.govOpened for recruitment
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
NCT03697850 · Phase 2 · France
Source: ClinicalTrials.govClosed for recruitment
NCT06511648 · Phase 2 · Spain, France, United Kingdom, Italy
Source: ClinicalTrials.govOpened for recruitment
The Impact of PDD During TURB for NMIBC
NCT06548438 · Phase 4 · Italy
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07566156 · Phase 3 · Canada, Germany, Spain, France, Italy, South Korea
Source: ClinicalTrials.govClosed for recruitment
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Systematic review
World journal of urology · PubMed
Systematic review
A systematic review on the possible role of microRNA-155 in cancer treatment.
Frontiers in pharmacology · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 14 Oct 2026
Phase 1/2Ended 30 Sept 2026
Completed35 participants
NCT06637423
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Phase 2Ended 22 Sept 2026
Phase 3Ended 15 Sept 2026
Completed99 participants
NCT06331299
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Phase 2Ended 4 Sept 2026
Completed131 participants
NCT02675829
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
No phaseEnded 1 Sept 2026
Completed60 participants
NCT07906626
Snakehead Fish Extract and Curcumin Co-Supplementation in Advanced Lung Cancer on Inflammation, Nutritional Status, and Quality of Life
No phaseEnded 26 Aug 2026
Completed7 participants
NCT05899361
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
Phase 2Ended 22 Aug 2026
Completed15 participants
NCT06257017
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Phase 2Ended 18 Aug 2026
Completed45 participants
NCT04562311
Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
No phaseEnded 13 Aug 2026
Completed450 participants
NCT03193528
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
- Prospective multicenter validation of a Urine-Based multiplex assay for risk stratification of patients presenting with gross hematuria. · Journal of the National Cancer Institute, 2026
Phase 2Ended 6 Aug 2026
Completed306 participants
2024-519288-17-00
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Phase 1Ended 5 Aug 2026
Completed22 participants
NCT06181266
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
Phase 1Ended 31 Jul 2026
No phaseEnded 31 Jul 2026
Completed2756 participants
NCT03782207
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Phase 1Ended 16 Jul 2026
Completed138 participants
NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Phase 1/2Ended 9 Jul 2026
No phaseEnded 30 Jun 2026
Completed360 participants
NCT06412848
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
Phase 2Ended 5 Jun 2026
Completed31 participants
NCT06059547
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
Phase 1/2Ended 2 Jun 2026
Completed98 participants
NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2Ended 27 May 2026
Phase 3Ended 19 May 2026
Completed709 participants
NCT02632409
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
- Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up. · BJU international, 2026
Phase 3Ended 18 May 2026
Phase 1Ended 28 Apr 2026
Completed7 participants
NCT05154994
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
Phase 3Ended 24 Apr 2026
Phase 1Ended 14 Apr 2026
Completed80 participants
NCT00479128
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
Phase 3Ended 14 Apr 2026
No phaseEnded 13 Apr 2026
Completed120 participants
NCT06955910
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
No phaseEnded 1 Apr 2026
Completed88 participants
NCT06307704
Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients
Phase 2Ended 31 Mar 2026
Completed163 participants
NCT04919512
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026
No phaseEnded 30 Mar 2026
No phaseEnded 30 Mar 2026
Completed1 participants
NCT07386847
A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer
No phaseEnded 23 Mar 2026
Completed72 participants
NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
No phaseEnded 17 Mar 2026
Completed140 participants
NCT06973161
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Phase 1Ended 16 Mar 2026
Completed102 participants
NCT05867121
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Phase 1Ended 3 Mar 2026
Completed19 participants
NCT01104350
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
No phaseEnded 9 Feb 2026
Completed190 participants
NCT04146064
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
Phase 2Ended 8 Feb 2026
Completed63 participants
NCT05077709
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
No phaseEnded 4 Feb 2026
Phase 2Ended 30 Jan 2026
Completed39 participants
NCT02690558
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
Phase 1Ended 9 Jan 2026
Completed51 participants
NCT05375903
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
No phaseEnded 5 Jan 2026
Phase 4Ended 31 Dec 2025
Completed120 participants
NCT03348969
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC
No phaseEnded 31 Dec 2025
No phaseEnded 31 Dec 2025
Completed240 participants
NCT07510685
Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)
Phase 2Ended Dec 2025
Completed78 participants
NCT02710734
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
No phaseEnded 30 Dec 2025
Completed127 participants
NCT06281691
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
No phaseEnded 22 Dec 2025
Completed70 participants
NCT07642102
Evaluation of the Role of Early Second Look TURBT in Management of High Risk Non Muscle Invasive Bladder Cancer
No phaseEnded 20 Dec 2025
No phaseEnded 19 Dec 2025
Completed220 participants
NCT05223491
En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer
No phaseEnded 15 Dec 2025
Phase 2Ended 15 Dec 2025
Completed60 participants
NCT02621151
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
Phase 1Ended 8 Dec 2025
Completed5 participants
NCT06894771
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Phase 2Ended 1 Dec 2025
Completed9 participants
NCT04701918
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
No phaseEnded 30 Nov 2025
Completed116 participants
NCT07347132
Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor
Phase 2Ended 28 Nov 2025
Completed38 participants
2024-511561-10-00
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Phase 3Ended 27 Nov 2025
No phaseEnded 12 Nov 2025
Phase 1Ended 12 Nov 2025
Completed220 participants
2024-511316-25-00
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma Morpheus-UC
Phase 3Ended 7 Nov 2025
Completed161 participants
NCT04157985
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
No phaseEnded 5 Nov 2025
Completed792 participants
NCT02704832
Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)
Not medical advice. fetched 6 Nov 2026